Other antimicrobials of interest in the era of extended-spectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline  by Garau, J.
REVIEW
Other antimicrobials of interest in the era of extended-spectrum
b-lactamases: fosfomycin, nitrofurantoin and tigecycline
J. Garau
Department of Medicine, Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain
ABSTRACT
The progressive increase of extended-spectrum b-lactamase (ESBL) -producing enteric bacteria in recent
years has called for a re-evaluation of current antibiotic therapy for these infections. The activity and
potential use of two old antimicrobials, nitrofurantoin and fosfomycin, and the new compound
tigecycline for treatment of infections due to ESBL-producing Enterobacteriaceae, with special emphasis
on E. coli, are reviewed. Fosfomycin continues to be active against the most common uropathogens; in a
recent survey from Spain, among the 428 ESBL-producing isolates, the resistance rate of E. coli to
fosfomycin was 0.3%, whereas the resistance rate of K. pneumoniae was 7.2%. Other recent surveys,
from other parts of the world, conﬁrm the activity of fosfomycin against ESBL-producing E. coli. The
rate of resistance to nitrofurantoin in recent surveys in the USA and Canada was 1.1% among 1142
isolates of E. coli from outpatient urinary isolates. However, among 115 clinical isolates of E. coli ESBL
producers, only 71.3% were sensitive to nitrofurantoin. Also, E. coli resistance to nitrofurantoin has been
reported to be high in a recent survey in Latin American hospitals and in Italy. Tigecycline is a
glycylcycline that circumvents efﬂux and ribosomal protection, the two most frequent genetic
mechanisms of tetracycline resistance. The recent activity of tigecycline against 285 nonclonally related
isolates expressing well-characterised ESBLs from hospital settings and the community reveal
susceptibility rates for tigecycline of 97.5%. Because responses to nitrofurantoin may be less satisfactory
and may require longer courses of therapy, nitrofurantoin is considered to be an alternative, rather than
a ﬁrst-line, therapeutic agent for this clinical syndrome. Fosfomycin trometamol is a safe and effective
alternative for the treatment of cystitis and asymptomatic UTI during pregnancy, and has become, in
many countries, the ﬁrst choice for treatment of any type of cystitis. Finally, for treatment of systemic
infections in the hospital setting, tigecycline could be an option that would reduce selection for ESBL-
producing organisms.
Keywords ESBL, Escherichia coli, fosfomycin, nitrofurantoin, review, tigecycline, urinary tract infection
Clin Microbiol Infect 2008; 14 (Suppl. 1): 198–202
INTRODUCTION
The progressive increase of extended-spectrum
b-lactamase (ESBL) -producing enteric bacteria in
recent years has generated the need to re-evaluate
current antibiotic therapy for these infections. The
matter is increasingly important today in coun-
tries where the prevalence of ESBL-producing
Escherichia coli has increased considerably at the
community level, fuelled by the emergence and
dissemination of CTX-M enzymes in this species
in many parts of the world [1]. The burden of
disease due to E. coli infections is enormous.
In the elderly population, the incidence of
community-onset E. coli bacteraemia was
150 cases ⁄ 100 000 person-years, which is approx-
imately three times higher than the rate of
pneumococcal bacteraemia in this population. It
is also substantially higher than the rates of
community-onset bacteraemia due to Staphylococ-
cus aureus, group A streptococci and group B
streptococci in persons ‡65 years of age, as esti-
mated from surveillance studies of other popula-
tions. These comparisons suggest that E. coli is the
most common cause of community-onset bacter-
aemia in the elderly population [2].
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The prevalence of CTX-M types has increased
dramatically since 1995 in many parts of the
world. All confer resistance to amino- and ureido-
penicillins, oxyimino-cephalosporins and mono-
bactams, but not to 7-a-substituted b-lactams. The
ESBL strains are increasingly associated with
resistance to other non-related antimicrobials
and pose signiﬁcant therapeutic challenges. This
associated resistance to other classes of antimi-
crobials is especially problematic in urinary iso-
lates and underscores the therapeutic challenge
that they represent.
In this article, the activity and potential use of
two old antimicrobials, nitrofurantoin and fosfo-
mycin, and the new compound tigecycline in
infections due to ESBL-producing Enterobacteri-
aceae, with special emphasis on E. coli, are
reviewed.
FOSFOMYCIN
Fosfomycin is a bactericidal antibiotic that acts as
a cell-wall inhibitor by interfering with the ﬁrst
step in peptidoglycan biosynthesis. It has a broad
spectrum of activity, with a wide therapeutic
range and characteristic pharmacological proper-
ties. It penetrates excellently into various tissues
[3] and cerebrospinal ﬂuid [4], and, in Europe, is
frequently administered in combination with
other antimicrobial agents to combat severe bac-
terial infections. It exerts bactericidal activity
under anaerobic conditions [5], as is the case
within encapsulated purulent lesions, and has
negligible protein-binding activity.
Resistance to fosfomycin develops rapidly in
E. coli under experimental conditions, but in spite
of the relatively high mutation rate in vitro,
resistance in clinical isolates is rare. In-vitro-
selected mutants show a decreased growth rate
in both the absence and presence of fosfomycin;
this provides an explanation for why most of the
resistant bacteria have difﬁculty in becoming
established in the bladder, due to their lowered
ﬁtness [6]. Also, many strains of E. coli can adhere
to the bladder epithelium, and, as a result, they
can be maintained in the bladder even though
their growth rate is below the threshold required
to prevent wash-out. Thus, if the antibiotic also
decreases adhesion, this might further prevent
bacterial establishment. Indeed, it has been shown
that fosfomycin decreases bacterial adhesion [7],
and this effect, conceivably, could also reduce
resistance development. Although the mutator
phenotypes found among E. coli expressing CTX-
M b-lactamases have an increased propensity to
fosfomycin resistance [8], this resistance remains
rare among E. coli expressing CTX-M enzymes in
countries with a high use of fosfomycin in the
treatment of urinary tract infections (UTIs) [9].
Fosfomycin tromethamine is a stable salt of
fosfomycin that is licensed for the single-dose
treatment of acute uncomplicated UTIs caused by
susceptible organisms. In-vitro time-kill kinetics
of fosfomycin against E. coli and Proteus mirabilis
show primarily concentration-dependent activity,
with a prolonged post-antibiotic effect [10]. After
oral administration of 3 g of the trometamine salt
of fosfomycin, high urinary concentrations (1000–
4000 mg ⁄L) are achieved, and concentrations
remain at 100 mg ⁄L for at least 30–40 h, guaran-
teeing good efﬁcacy in the treatment of uncom-
plicated UTI even after a single administration
[11].
After many years of fosfomycin use, fosfomycin
continues to be active against the most common
uropathogens, and there is a very low incidence
of resistant strains in E. coli (c. 2%). It is becoming
increasingly common to isolate ESBL-producing
E. coli from outpatients with uncomplicated UTIs.
It is common to ﬁnd that the same plasmid coding
for ESBL also contains genes conferring resistance
to several groups of antimicrobial agents, such as
aminoglycosides and co-trimoxazole. The concur-
rence of quinolone resistance, particularly in
ESBL-producing Klebsiella pneumoniae, is frequent,
there being few alternatives for the appropriate
oral treatment of uncomplicated UTIs caused by
ESBL-producing microorganisms.
In a recent survey done in Spain, among the 428
ESBL-producing isolates studied, 417 (97.4%)
were susceptible to fosfomycin (MIC £64 mg ⁄L).
The resistance rate of E. coli to fosfomycin was
0.3%, whereas the resistance rate of K. pneumoniae
was 7.2%. Co-trimoxazole and ciproﬂoxacin
were the least active antibiotic agents against
ESBL-producing isolates (sensitivity <50%). Only
one strain of E. coli, among all 290 tested,
showed intermediate susceptibility to fosfomycin
(MIC 128 mg ⁄L). K. pneumoniae isolates had the
highest MICs for fosfomycin (MIC50 and MIC90 of
16–64 mg ⁄L) but are still within the susceptible
range, whereas more than 90% of E. coli isolates
showed very low MICs (£4 mg ⁄L) [9]. These
results are similar to those described in previous
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reports of non-ESBL-producing isolates, conﬁrm-
ing that fosfomycin retains its activity against
ESBL-producing isolates, and that cross-resistance
with other classes of antimicrobial agent is not a
problem at present. Also, there were no differ-
ences in fosfomycin activity against strains
expressing different types of ESBL [9]. Other
recent surveys in other parts of the world conﬁrm
the activity of fosfomycin against ESBL-produc-
ing E. coli. Thus, among 307 E. coli isolates col-
lected from urine and blood from patients at a
Korean tertiary-care hospital, all but one isolate
was susceptible to fosfomycin (MIC90) 16 mg ⁄L),
regardless of the sources of the isolates, cipro-
ﬂoxacin resistance, and ESBL production [12].
NITROFURANTOIN
Nitrofurantoin is a synthetic nitrofuran antimicro-
bial agent that has been used for more than
50 years. It still has a role and continues to be
prescribed, particularly in the ambulatory setting
for uncomplicated UTIs, especially in its
macro-crystalline formulation, macrodantin. The
mechanism of action of nitrofurantoin is not
well-understood, but activity appears to require
enzymatic reduction within the bacterial cell [13].
The reduced derivatives appear to be capable of
binding to ribosomal proteins. Antibacterial activ-
ity has also been shown under conditions in which
nitroreductase activity was inhibited, suggesting
that nitrofurantoinmay act, in part, without reduc-
tion to activemetabolites [13]. Susceptibility break-
points are based on urinary concentrations of
nitrofurantoin and have been correlated with
eradication of bacteriuria in patients with UTIs.
Strains with MIC £32 mg ⁄L are considered to be
sensitive. On the basis of this criterion, >90% of
clinical strains of E. coli and Citrobacter spp. are
sensitive. In contrast, only a minority of strains of
Enterobacter spp. (20%) and Klebsiella spp. (45%)
are susceptible, andmembers of the generaProteus,
Providencia, Morganella, Serratia, Acinetobacter and
Pseudomonas are almost always resistant [13].
Resistant strains of E. coli, with chromosomal
or plasmid-mediated resistance, have been asso-
ciated with inhibition of nitrofuran reductase
activity, thereby decreasing the production of
the active derivative. However, the emergence of
nitrofurantoin-resistant variants from initially
susceptible pathogens has been rare, despite
many years of clinical use.
The rate of resistance to nitrofurantoin in recent
surveys in the USA and Canada was 1.1% among
1142 isolates of E. coli from outpatient urinary
isolates [14]. Very similar results were found in
France; 1.8% of all urinary E. coli isolates were
sensitive to nitrofurantoin in 2005 [15]. However,
among 115 clinical isolates of E. coli ESBL pro-
ducers, only 71.3% were sensitive to nitrofuran-
toin [16]. Also, E. coli resistance to nitrofurantoin
has been reported to be high in a recent survey in
Latin American hospitals (13%) [17] and in Italy
(20%) [18]. In K. pneumoniae, the ESBL producers
had signiﬁcantly diminished susceptibility, as
compared with a non-ESBL producer, to nitrofur-
antoin (p <0.001) [19].
Absorption of oral nitrofurantoin is 40–50%,
and this is enhanced when it is taken with food;
serum concentrations are low to undetectable,
and urine concentrations are 50–250 mg ⁄L. It
should not be used in patients with renal failure.
TIGECYCLINE
Tigecycline is a glycylcycline derivative of mino-
cycline with in-vitro bacteriostatic activity. It has a
broad antibacterial spectrum, including Gram-
positive, Gram-negative, atypical and anaerobic
bacteria [20,21]. Tigecycline circumvents efﬂux
and ribosomal protection, the two most frequent
genetic mechanisms of tetracycline resistance, and
has MICs <2 mg ⁄L for Enterobacteriaceae except
proteae [21,22]. It is also unaffected by the
presence of co-resistance to unrelated antimicro-
bials, such as b-lactams, aminoglycosides and
quinolones.
The activities of tigecycline against 285 non-
clonally related isolates (172 from E. coli, 84 from
Klebsiella spp., 20 from Enterobacter spp., ﬁve from
Salmonella spp., and four from Citrobacter spp.)
expressing well-characterised ESBLs from hospi-
tal and the community area of inﬂuence have
been recently reported from Madrid, Spain. Sus-
ceptibility rates for tigecycline were 97.5%; tige-
cycline (mode MIC 0.5 mg ⁄L; MIC90 1 mg ⁄L) was
four- to 256-fold more active than doxycycline
and minocycline (mode MIC range 2–128 mg ⁄L).
CTX-Ms were the most frequent ESBLs (61.4%),
65.8% in community isolates and 58.6% in nos-
ocomial isolates. SHV and TEM variants consti-
tuted 22.8% and 15.8% of the ESBLs, respectively.
Overall co-resistance rates were as follows:
gentamicin, 27.4%; tobramycin, 27.4%; amikacin,
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6.7%. Resistance levels of sulfonamide (61.7%),
trimethoprim (52.3%) and ciproﬂoxacin (37.2%)
were signiﬁcantly (p <0.001) associated with
CTX-M-9 producers. No tigecycline resistance
was observed, although seven K. pneumoniae iso-
lates exhibited intermediate MICs (4 mg ⁄L) [23].
Among a collection of 846 ESBL-producing and
AmpC-hyperproducing Enterobacteriaceae from
the UK, 703 (83%) were susceptible at the
EUCAST breakpoint of £1 mg ⁄L; 108 (12.7%)
were intermediate, with MICs of 2 mg ⁄L, and 35
(4.1%) were resistant, with MICs of >2 mg ⁄L. In
the case of E. coli, 99% (417 ⁄ 420) of the tigecycline
MICs fell between 0.125 and 1 mg ⁄L, and only
three isolates, all hyperproducers of AmpC, were
intermediate, with none being resistant [24].
CONCLUSION
The emergence of ESBL-producing E. coli limits
the therapeutic options considerably. Not only are
most b-lactams no longer active, but the associ-
ated co-resistance reduces the options even fur-
ther. In this scenario, alternative antimicrobial
compounds are needed to cover infections in
which these isolates are increasingly involved.
In the outpatient setting, high resistance rates
for b-lactams, co-trimoxazole and ﬂuoroquinol-
ones restrict empirical antibiotic use. The efﬁcacy
of amoxicillin–clavulanate in the treatment of
ESBL-producing E. coli strains that are sensitive
to this combination has not been well-established;
although, in the case of E. coli UTI, it can cure the
infection, the current prevalence of resistance to
amoxicillin–clavulanate in E. coli of 10% or more
in some parts of the world limits considerably its
therapeutic use for this indication. For this reason,
nitrofurantoin and fosfomycin became reasonable
alternatives for the treatment of uncomplicated
UTIs.
Nitrofurantoin is restricted to treatment or
prevention of uncomplicated cystitis; among its
indications are the treatment of UTI during
pregnancy when clearly indicated, but it should
not be used at term.
Because responses to this agent and infections
caused by susceptible pathogens may be less
satisfactory and require longer courses of therapy,
nitrofurantoin is considered to be an alternative
rather than a ﬁrst-line therapeutic agent for this
clinical syndrome. On the other hand, the use of
nitrofurantoin is unlikely to lead to cross-resis-
tance to those antimicrobials that are used to treat
other important infections.
Fosfomycin trometamol is a safe and effective
alternative in the treatment of cystitis and of
asymptomatic UTI in pregnancy. Recently, its use
has increased dramatically in certain countries,
and it has become the ﬁrst choice for any type of
cystitis [25].
In systemic infections in the hospital setting,
tigecycline, in the absence of cross-resistance with
other compounds, could represent an opportunity
to reduce the intensity of selection for ESBL-
producing organisms derived from the use of
other antimicrobial agents. Co-resistance, such as
that found in a signiﬁcant proportion of ESBL-
producing isolates, precludes the empirical use of
most of the antimicrobial families, particularly in
the case of severe infections. The efﬁcacy of the
combination of a b-lactam and a b-lactamase
inhibitor is unclear, as treatment failures have
been reported. Carbapenems represent the ﬁrst
option when these infections are caused by ESBL
producers, although this option is jeopardised by
the presence of strains producing metallo-b-lac-
tamases. In-vitro data support the assumption
that tigecycline can also be considered an alter-
native for infections involving multiresistant
ESBL-producing isolates. In the case of UTI, it
remains to be seen whether the low concentra-
tions of tigecycline attained in the urine are
sufﬁcient to eradicate the infection caused by
strains of Klebsiella and Enterobacter with interme-
diate resistance to the compound [24].
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